

ADY 1617
Pfw

CERTIFICATE OF MAILING
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

October 5, 2004
Date


Shelley P.M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe Sophia Ran and
Rolf A. Brekken (As Amended)

Serial No.: 09/351,149

Filed: July 12, 1999

For: CANCER TREATMENT KITS COMPRISING
THERAPEUTIC CONJUGATES THAT BIND
TO AMINOPHOSPHOLIPIDS

Group Art Unit: 1617

Examiner: Sharareh, S.

Atty. Dkt. No.: 3999.002383

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22131-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

A Final Official Action has been received in the present application. However, this Supplemental Information Disclosure Statement is being submitted in an abundance of caution and should be enterable under 37 C.F.R. § 1.97(d) in light of the following information. In the alternative, for completeness and to most fully comply with the duty of disclosure, the enclosed document should be placed in the file in accordance with 37 C.F.R. § 1.97(i).

In accordance with 37 C.F.R. § 1.97(e)(2), it is hereby certified that the documents listed in the accompanying Form PTO-1449 were not cited in a communication from a foreign patent office in a counterpart foreign application. The listed documents were identified during research conducted by legal representatives of the licensee of the present application in connection with the licensee's Opposition against a European patent to another. The research was initiated on about July 20, 2004, and was completed on August 20, 2004, and the present statement is being filed within three months of the initiation of the research.

No fees should be due in connection with the filing of this Supplemental Information Disclosure Statement. However, should any fees under 37 C.F.R. §§ 1.97(d) and 1.17(p) be due, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/3999.002383.

Respectfully submitted,
Williams, Morgan & Amerson, P.C.
Customer No. 23720



Shelley P.M. Fussey, Ph.D.
Reg. No. 39,458
Agent for Applicants

10333 Richmond, Suite 1100
Houston, Texas, 77042
(713) 934-4079
Date: October 5, 2004

Form PTO-1449 (modified)

Atty. Docket No.

3999.002383

Serial No.

09/351,149

List of Patents and Publications for Applicant's

Applicant

Thorpe, Ran and Brekken

INFORMATION DISCLOSURE STATEMENT

Filing Date:

July 12, 1999

Group:

1617

(Use several sheets if necessary)

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Pages 1-2

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No


Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C113	Auerbach, "Vascular Endothelial Cell Differentiation: Organ-Specificity and Selective Affinities as the Basis for Developing Anti-Cancer Strategies," <i>Int. J. Radiat. Biol.</i> , 60(1/2):1-10, 1991.
	C114	Brown <i>et al.</i> , "Leaky Vessels, Fibrin Deposition, and Fibrosis: A Sequence of Events Common to Solid Tumors and to Many Types of Disease," <i>Am. Rev. Respir. Dis.</i> , 140:1104-1107, 1989.
	C115	Clauss <i>et al.</i> , "Vascular Permeability Factor: A Tumor-Derived Polypeptide that Induces Endothelial Cell and Monocyte Procoagulant Activity, and Promotes Monocyte Migration," <i>J. Exp. Med.</i> , 172:1535-1545, 1990.
	C116	Denekamp, "Vasculature as a Target for Tumour Therapy," <i>Prog. Appl. Microcirc.</i> , 4:28-38, 1984.
	C117	Dvorak <i>et al.</i> , "Vascular Permeability Factor, Fibrin, and the Pathogenesis of Tumor Stroma Formation," <i>Ann. N.Y. Acad. Sci.</i> , 667:101-111, 1992.
	C118	Dvorak, "Leaky Tumor Vessels: Consequences for Tumor Stroma Generation and for Solid Tumor Therapy," <i>Progress in Clinical and Biological Research</i> , 354a: 317-330, 1990.
	C119	Dvorak, "Tumors: Wounds That Do Not Heal," <i>New Eng. J. Med.</i> , 315(26):1650-1659, 1986.
	C120	Dvorak <i>et al.</i> , "Regulation of Extravascular Coagulation by Microvascular Permeability," <i>Science</i> , 227:1059-1061, 1985.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.

3999.002383

Serial No.

09/351,149

Applicant

Thorpe, Ran and Brekken

Filing Date:

July 12, 1999

Group:

1617

U.S. Patent Documents

See Page

Foreign Patent Documents

See Page

Other Art

See Pages 1-2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C121	Dvorak <i>et al.</i> , "Fibrin as a Component of the Tumor Stroma: Origins and Biological Significance," <i>Cancer Metastasis Reviews</i> , 2:41-73, 1983.
	C122	Folkman and Ingber, "Inhibition of Angiogenesis," <i>Seminars in Cancer Biology</i> , 3:89-96, 1992.
	C123	Folkman and Shing, "Angiogenesis," <i>J. Biol. Chem.</i> , 267(16):10931-10934, 1992.
	C124	Folkman <i>et al.</i> , "Induction of Angiogenesis During the Transition from Hyperplasia to Neoplasia," <i>Nature</i> , 339:58-61, 1989.
	C125	Folkman, "What is the Evidence that Tumors are Angiogenesis Dependent?," <i>J. Natl. Cancer Inst.</i> , 82(1):4-6, 1990.
	C126	Folkman and Klagsbrun, "Angiogenic Factors," <i>Science</i> , 235:442-447, 1987.
	C127	Greenblatt and Shubi, "Tumor Angiogenesis: Transfilter Diffusion Studies in the Hamster by the Transparent Chamber Technique," <i>J. Natl. Cancer Inst.</i> , 41:111-124, 1968.
	C128	Jain, "Haemodynamic and Transport Barriers to the Treatment of Solid Tumours," <i>Int. J. Radiat. Biol.</i> , 60(1/2):85-100, 1991.
	C129	Kerbel, "Inhibition of Tumor Angiogenesis as a Strategy to Circumvent Acquired Resistance to Anti-Cancer Therapeutic Agents," <i>BioEssays</i> , 13(1):31-36, 1991.
	C130	Weidner, "Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma," <i>New. Eng. J. Med.</i> , 324(1):1-7, 1991.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.